Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-058-7 | CAS number: 102-82-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The read-across substance tributylamine hydrochloride is rapidly and nearly completly absorbed after oral application. Excretion is mainly via urine (about 70%), to a minor extent via air (about 28%) and only small amounts are excreted via faeces (up to 4%). Chain hydroxylated and debutylated metabolites were identified in urine as well as the unchanged test item.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
Additional information
Two studies (RL2) are available on the toxicokinetics and metabolism of the test compound.
In the Hoechst AG (1990a) study, Wistar rats were given a single oral dose of 50 mg radiolabeled tributylamine hydrochloride/kg body weight. The oral absorption was complete. Maximum blood levels were determined in males within 4-8 h post application, in females within 4-6 h after dosing. The elimination of the blood was biphasic with half lives of 5.0 and 65.4 h in females and 6.6 and 69.8 h in males, respectively. 27.8% of the administered dose was found in the expired air within 48 h, 69.4 % in the urine and 3.7 % in the faeces within 7 days (only male animals tested). The excretion was biphasic with half lives of 4.6 and 42.3 in urine and 6.4 h and 48.9 h in faeces, respectively. The highest concentrations of radioactivity were found in urinary bladder (0.73 µg equivalents/g), followed by retroperitoneal fat (0.61 µg equivalents/g), liver (0.48 µg equivalents/g), subcutaneous fat (0.46 µg equivalents/g), bones (0.43 µg equivalents/g) and lung (0.40 µg equivalents/g). The kidneys, brain, pancreas, gonads, and heart contained 0.4 -0.2 µg equivalents/g, stomach, skeletal muscle and smooth muscle few below 0.2 µg equivalents/g and the other tissues were at or below detection limit. 0.51 % was retained in the examined organs 1 week post application, the highest amount (0.2 %) was observed in the skeletal muscle. According to the authors these slight differences between the contents of organs indicate the metabolism of the test substance to endogenous substances, which are incorporated into the organism. The recovery of excreted material and radioactivity in the organs was complete.
In summary, Wistar rats received orally 50 mg TBA-HCl/kg bw. The substance contained a radiolabel: [14]C: Butyl*-N-(butyl)2. The substance was rapidly absorbed, metabolised, and excreted. Excretion was complete, and only a small percentage of the administered dose remained in the carcass. Key findings are tabulated below.
radioactivity in |
% of dose (approx. means) |
Air (= CO2) |
28 (48 hrs) |
urine |
70 (48 hrs) |
Faeces |
4 (48 hrs) |
Organs |
0.5 (7days) |
Organ distribution |
Uniform and low (µg Eq./g tissue) (urinary baldder 0.73 retroperitoneal fat 0.61 Liver 0.48 Subcutaneous fat 0.46 Bone 0.43 Lung 0.4 |
|
Sum: 104 +/- |
In a second study (Hoechst AG, 1990b) the urinary metabolites from the above experiment were characterised. The unchanged test substance and the identified urinary metabolites accounted for approx. 86 % of the total radioactivity in urine. The unchanged test substance accounted for 10%; chain hydroxylation for 60%; and deamination to Di-n-butylamine derivatives for approx. 33% of the administered dose. 14% were unidentified. The table below gives details. (Hoechst, 1990b).
Metabolite In urine |
% of dose (approx. means) |
Butyl*-N-(butyl)2 |
10 (unchanged TS) |
(Butyl)2-N-butyl-OH |
25 |
Butyl-N-(butyl-OH)2 |
19 |
Butyl-NH-butyl-OH2 |
12.5 |
Butyl-NH-butyl |
20 |
2 peaks unidentified |
10 + 4 |
It is concluded that deamination is not the sole metabolic pathway, but the secondary amine is formed to approx. 33% from the tertiary amine which justifies a vertical read across between the tertiary amine and the respective secondary amine. Further, C-hydroxylation is a major pathway fur tri-n-butylamine. This is also expected to hold true for more lipophilic substituents with larger chain length.
Tributylamine is caustic and no information is available on dermal absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.